Open label, comparative, randomized, multicenter, study of trastuzumab given with docetaxel versus sequential single agent therapy with trastuzumab followed by docetaxel as first-line treatment for Her2neu+++ metastatic breast cancer patients.
Phase of Trial: Phase II
Latest Information Update: 08 May 2012
At a glance
- Drugs Docetaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms HERTAX
- 08 May 2012 Additional lead trial centers identified as reported by Netherlands Trial Register.
- 08 May 2012 Additional trial location added as reported by Netherlands Trial Register.
- 08 May 2012 New source identified and integrated (NTR308: Netherlands Trial Register).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History